

Lipigon Q4 2022 - Rights issue and Progress with Lipisense

Redeye comments on the progress of the phase I trial of Lipisense and the 2023 rights issue, which renders a new Base Case.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Lipigon Q4 2022 - Rights issue and Progress with Lipisense](#)